The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Employment - Incyte
Stock and Other Ownership Interests - Incyte
ECHO-306/KEYNOTE-715: A phase 3 study of first-line epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus platinum-based chemotherapy plus placebo for metastatic non–small cell lung cancer (mNSCLC).
 
Rina Hui
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Consulting or Advisory Role - AstraZeneca; MSD; Novartis; Roche
Travel, Accommodations, Expenses - Roche
 
Mihaela Munteanu
No Relationships to Disclose
 
Yufan Zhao
Employment - Amgen (I); Incyte
Stock and Other Ownership Interests - Incyte
Travel, Accommodations, Expenses - Amgen (I)
 
Yiwen Luo
No Relationships to Disclose
 
Ayman Samkari
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Marina Chiara Garassino
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Roche
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Lilly; MSD Oncology; Pfizer
Other Relationship - Roche/Genentech; Roche/Genentech